GNH USA

Europe — EMA

Laziros

GNH USA supplies Laziros (Azacitidine), a DNA methyltransferase inhibitor for myelodysplastic syndromes and acute myeloid leukemia.

Azacitidine

Request sourcing

1
Pack/s

What is Azacitidine?

Azacitidine, the active ingredient in Laziros, is a DNA methyltransferase inhibitor presented as a subcutaneous injection for subcutaneous use. It treats myelodysplastic syndromes and acute myeloid leukemia in adult patients. GNH USA supplies Laziros as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Azacitidine used for?

Azacitidine is employed in hematologic malignancies and related disorders. Myelodysplastic syndromes (MDS): Improves peripheral blood counts and can delay progression to acute leukemia. Acute myeloid leukemia (AML): Provides cytoreductive activity and may achieve remission in eligible patients.

What are the side effects of Azacitidine?

Azacitidine may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate upset stomach often occurring after injection. - Fatigue: generalized tiredness that may affect daily activities. - Injection site reactions: redness, swelling or pain at the subcutaneous site.

Serious or Rare Side Effects: - Cytopenias: significant reductions in blood cell lines requiring close monitoring. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Tumor lysis syndrome: rapid tumor cell breakdown leading to metabolic disturbances. - Severe allergic reactions: anaphylaxis or hypersensitivity requiring immediate medical attention.

What precautions apply to Azacitidine?

Azacitidine requires careful monitoring and specific safety measures. - Monitor blood counts: regular CBC testing to detect cytopenias. - Assess infection risk: watch for fever, chills, or signs of infection. - Evaluate organ function: check hepatic and renal parameters before and during therapy. - Pregnancy and lactation: use only if benefits outweigh potential risks; discuss with a specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

What does Azacitidine interact with?

Azacitidine may interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Antimetabolites (e.g., cytarabine): may increase myelosuppression. - Strong CYP enzyme inducers: could reduce azacitidine exposure. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor coagulation parameters for bleeding risk. - Immunosuppressants: adjust dosing and monitor for additive immunosuppression.

Frequently asked questions

What conditions is Laziros used to treat?+
Laziros, which contains azacitidine, is indicated for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in adult patients. These are hematologic disorders where abnormal blood cell production occurs, and azacitidine helps restore normal cell function.
How does azacitidine work in the body?+
Azacitidine is incorporated into RNA and DNA during cell replication. In DNA, it inhibits DNA methyltransferase, leading to hypomethylation and re‑activation of tumor suppressor genes. In RNA, it disrupts protein synthesis, together causing cytotoxic effects on abnormal hematopoietic cells.
What is the usual dose of Laziros?+
The specific dose and schedule of Laziros are determined by the prescribing physician based on the patient’s condition, disease severity, and clinical response. Dosage may be adjusted according to blood count monitoring and tolerance.
Is Laziros safe to use during pregnancy or breastfeeding?+
Safety data for azacitidine in pregnancy and lactation are limited. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and this decision must be made by a qualified healthcare professional.
How do I order Laziros from GNH USA?+
To order Laziros, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.
How does Laziros compare with other treatments for MDS and AML?+
Azacitidine belongs to the DNA methyltransferase inhibitor class, offering a distinct mechanism compared with conventional chemotherapy. It is often preferred for patients who may not tolerate intensive regimens, providing disease‑modifying benefits and a different safety profile.
What are the storage requirements for Laziros?+
Laziros should be stored refrigerated at 2‑8 °C. Keep the product in its original container, protect it from light, and avoid freezing or shaking the solution to maintain stability and potency.
How is Laziros administered?+
Laziros is given as a subcutaneous injection, typically by a healthcare professional. The injection site is rotated to reduce local irritation, and the administration schedule is set by the treating physician.
What are the most serious risks associated with Laziros?+
The most serious risks include severe cytopenias (low blood counts), infections, tumor lysis syndrome, and rare but severe allergic reactions. Patients should be monitored closely for signs of infection, bleeding, or sudden metabolic changes.
Who should not use Laziros?+
Laziros is contraindicated in patients with known hypersensitivity to azacitidine or any of its excipients. It should also be avoided in individuals with uncontrolled infections or severe organ dysfunction unless the treating physician determines that the benefits outweigh the risks.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Azacitidine
Route
Subcutaneous Use
Manufacturer
Stada Arzneimittel Ag
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU